Cipla Ltd

Large Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Cipla Ltd has approved a significant $100 million investment in its subsidiary Cipla (EU) and appointed P R Ramesh as Vice-Chairman, effective April 1.

Cipla Announces Leadership Change and Major Investment - 20 Mar, 2026

Cipla has approved a significant investment in Cipla (EU) Limited and plans to merge with Inzpera Health Sciences. However, the stock shows bearish trends, indicating ongoing weakness.

Cipla Approves Investment Amid Ongoing Stock Weakness - 19 Mar, 2026

Morgan Stanley has maintained an Underweight rating on Cipla with a target price of Rs 1,211, citing concerns over Lanreotide injection batch recalls that may delay US resupply and impact market share, potentially affecting earnings for FY27–FY28.

Morgan Stanley Maintains Underweight on Cipla - 11 Mar, 2026

Cipla USA, a subsidiary of Cipla Ltd, has announced a recall of unexpired batches of Lanreotide Injection, leading to temporary supply shortages in the market.

Cipla USA Recalls Lanreotide Injection Batches - 10 Mar, 2026

Cipla USA, a subsidiary of Cipla Ltd, is recalling over 400 cartons of Nilotinib Capsules due to manufacturing issues. This Class III voluntary recall is not expected to cause adverse health consequences.

Cipla Recalls Nilotinib Capsules in the US - 08 Mar, 2026

Cipla Limited has entered a joint venture with Kemwell Biopharma to develop biologic products, investing ₹10 crore. Additionally, Cipla established a subsidiary in Saudi Arabia.

Cipla Forms Joint Venture and New Subsidiary - 02 Mar, 2026

Cipla's stock fell 2% after the US FDA designated a Greek facility as OAI, affecting Lanreotide production. The company's Q3FY26 net profit dropped 57% YoY. LIC increased its stake in Cipla to 9.091%.

Cipla Faces Challenges Amid FDA OAI Designation - 23 Feb, 2026

Cipla's subsidiary, Pharmathen, underwent a USFDA inspection that was classified as 'Official Action Indicated,' indicating potential regulatory concerns.

Cipla Faces USFDA Inspection Challenges - 21 Feb, 2026

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Retail Investor have increased holdings from 15.94% to 16.08% in Dec 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Up

In the last 3 years, Torrent Pharmaceuticals Ltd has given 181.2% return, outperforming this stock by 135.7%

This section gives you an insight into how the peers have performed as compared to this company in the last 3 years.

Against Peers

Promoters holdings remained unchanged at 29.13% of holdings in Dec 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

In the last 1 year, Torrent Pharmaceuticals Ltd has given 30.5% return, outperforming this stock by 48.1%

This section gives you an insight into how the peers have performed as compared to this company in the last 1 year.

In the last 7 days, CIPLA stock has moved down by -3.4%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Dip

Mutual Funds have decreased holdings from 20.17% to 19.16% in Dec 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Down

Revenue is down for the last 2 quarters, 7.85K Cr → 7.28K Cr (in ₹), with an average decrease of 7.4% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Fall

Netprofit is down for the last 2 quarters, 1.35K Cr → 675.8 Cr (in ₹), with an average decrease of 50.0% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Down

Foreign Institutions have decreased holdings from 24.47% to 23.86% in Dec 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Down

S&P BSE SENSEX 50

NIFTY 50

Nifty50 Value 20

Nifty100 Eq Weig

Nifty Healthcare

BSE MFG

Nifty 500

S&P BSE Dividend Stability

NIFTY PHARMA

Nifty LargeMidcap 250

NIFTY 100

S&P BSE Low Volatility

S&P BSE 100 LargeCap TMC

Nifty100 Low Volatility 30

BSE 200

BSE Healthcare

S&P BSE 100 ESG

BSE 500

BSE 100

S&P BSE 250 LargeMidCap

Nifty 200

HDFC Flexi Cap Fund -Direct Plan - Growth Option

Parag Parikh Flexi Cap Direct Growth

HDFC Focused Fund -Direct Plan - Growth Option

SBI ELSS Tax Saver Fund Direct Growth

ICICI Prudential Value Fund Direct Plan Growth

Cipla Ltd’s net profit fell -56.97% since last year same period to ₹675.80Cr in the Q3 2025-2026. On a quarterly growth basis, Cipla Ltd has generated -49.98% fall in its net profits since last 3-months.

Name	Value	Action
MACD level (12,26)	0.69	Bullish
CCI (20)	-23.17	Neutral
RSI (14)	59.83	Neutral
Momentum (10)	1.8	Bullish
ADI (14)	26.57	Bullish
Ultimate Oscillator (7,14,28)	64.19	Neutral

Name	Value	Action
SMA (20)	1256.93	Bullish
EMA (20)	1256.58	Bullish
VWMA (20)	1256.92	Bullish
SMA (50)	1254.75	Bullish
EMA (50)	1255.7	Bullish
SMA (200)	1256.52	Bullish
EMA (200)	1256.18	Bullish
KAMA (200)	1254.67	Bullish
DEMA (200)	1256.01	Bullish

Cipla Ltd (CIPLA)

Summary

Overall

Oscillators

Moving Averages